Search Results - "Hausman, Diana"

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors by HONG, David S, BOWLES, Daniel W, PETERSON, Scott, HAUSMAN, Diana F, KURZROCK, Razelle, JIMENO, Antonio, FALCHOOK, Gerald S, MESSERSMITH, Wells A, GEORGE, Goldy C, O'BRYANT, Cindy L, VO, Alex C. H, KLUCHER, Kevin, HERBST, Roy S, GAIL ECKHARDT, S

“…The objectives of the study were to evaluate the maximum tolerated dose (MTD), safety, pharmacodynamics, pharmacokinetics, and antitumor activity of PX-866 in…”
Get full text

Interferon Lambda as a Potential New Therapeutic for Hepatitis C by Miller, Dennis M., Klucher, Kevin M., Freeman, Jeremy A., Hausman, Diana F., Fontana, David, Williams, Doug E.

“…Interferon lambdas (IFN‐λ) are Type III interferons with biological activity, including induction of antiviral genes, similar to Type I IFNs, but signal…”
Get full text

Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma by THOMPSON, John A, CURTI, Brendan D, REDMAN, Bruce G, BHATIA, Shailender, WEBER, Jeffrey S, AGARWALA, Sanjiv S, SIEVERS, Eric L, HUGHES, Steven D, DEVRIES, Todd A, HAUSMAN, Diana F

“…A phase I study of patients with metastatic malignant melanoma (MM) and renal cell carcinoma (RCC) evaluated the safety and maximum tolerated dose (MTD),…”
Get full text

Phase II study of PX-866 in recurrent glioblastoma by Pitz, Marshall W, Eisenhauer, Elizabeth A, MacNeil, Mary V, Thiessen, Brian, Easaw, Jacob C, Macdonald, David R, Eisenstat, David D, Kakumanu, Ankineedu S, Salim, Muhammad, Chalchal, Haji, Squire, Jeremy, Tsao, Ming Sound, Kamel-Reid, Suzanne, Banerji, Shantanu, Tu, Dongsheng, Powers, Jean, Hausman, Diana F, Mason, Warren P

“…Glioblastoma (GBM) is the most aggressive malignancy of the central nervous system in adults. Increased activity of the phosphatidylinositol-3-OH kinase (PI3K)…”
Get full text

A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins by Keysar, Stephen B., Astling, David P., Anderson, Ryan T., Vogler, Brian W., Bowles, Daniel W., Morton, J. Jason, Paylor, Jeramiah J., Glogowska, Magdalena J., Le, Phuong N., Eagles-Soukup, Justin R., Kako, Severine L., Takimoto, Sarah M., Sehrt, Daniel B., Umpierrez, Adrian, Pittman, Morgan A., Macfadden, Sarah M., Helber, Ryan M., Peterson, Scott, Hausman, Diana F., Said, Sherif, Leem, Ted H., Goddard, Julie A., Arcaroli, John J., Messersmith, Wells A., Robinson, William A., Hirsch, Fred R., Varella-Garcia, Marileila, Raben, David, Wang, Xiao-Jing, Song, John I., Tan, Aik-Choon, Jimeno, Antonio

“…Targeted therapy development in head and neck squamous cell carcinoma (HNSCC) is challenging given the rarity of activating mutations. Additionally, HNSCC…”
Get full text

Sargramostim for Active Crohn's Disease by Korzenik, Joshua R, Dieckgraefe, Brian K, Valentine, John F, Hausman, Diana F, Gilbert, Mark J

“…In this randomized trial, sargramostim (a recombinant granulocyte–macrophage colony-stimulating factor) was not significantly more likely than placebo to…”
Get full text

Interleukin 21: combination strategies for cancer therapy by Smyth, Mark J, Sivakumar, Pallavur V, Skak, Kresten, Kragh, Michael, Hausman, Diana

“…Key Points Immunotherapy has increasingly become a focus area for cancer therapy, which has been stimulated by the recent advances in our understanding of the…”
Get full text

1384 LNK101, a highly differentiated T-cell engager (TCE) targeting CD3 and mesothelin (MSLN) in solid tumors by Santiago, Linda, Bandaranayake, Ashok, Correnti, Colin, Lin, Ida, Chan, Man Kid, Delbecq, Scott, Clarke, Midori, Carter, Jane, Gruff, Eric, Bracken, William, Meininger, David, Hausman, Diana, Mehlin, Christopher

“…BackgroundMSLN is a membrane protein overexpressed by many cancers with limited expression in normal tissues. One challenge in developing MSLN-targeted…”
Get full text

Phase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Non–Hodgkin's Lymphoma by ANSELL, Stephen M, WITZIG, Thomas E, NOVAK, Anne J, INWARDS, David J, PORRATA, Luis F, YTHIER, Arnaud, FERRANDE, Lee, NESTOROV, Ivan, DEVRIES, Todd, DILLON, Stacey R, HAUSMAN, Diana

“…Purpose: B-lymphocyte stimulator and a proliferation-inducing ligand regulate B-cell homeostasis and immunoglobulin production and are overexpressed in B-cell…”
Get full text

Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic by Andersen, Henrik, Meyer, Jeff, Freeman, Jeremy, Doyle, Sean E, Klucher, Kevin, Miller, Dennis M, Hausman, Diana, Hillson, Jan L

“…Chronic infection with hepatitis C virus (HCV) is estimated to affect approximately 3% of the world's population and cause 350,000 deaths each year. For a…”
Get full text

Phase 1/2 study of BLU-451, a central nervous system (CNS) penetrant, small molecule inhibitor of EGFR, in incurable advanced cancers with EGFR exon 20 insertion (ex20ins) mutations by Spira, Alexander I., Yu, Helena Alexandra, Sun, Lova, Nguyen, Danny, Pearson, Paul, Shim-Lopez, Jennifer, Hausman, Diana Felice, Le, Xiuning

“…TPS9155 Background: Oncogenic EGFR ex20ins mutations, found in ̃2% of non-small cell lung cancers (NSCLC) and a small percentage of other cancers, are…”
Get full text

A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer by Jimeno, Antonio, Bauman, Julie E, Weissman, Charles, Adkins, Douglas, Schnadig, Ian, Beauregard, Patrice, Bowles, Daniel W, Spira, Alexander, Levy, Benjamin, Seetharamu, Nagashree, Hausman, Diana, Walker, Luke, Rudin, Charles M, Shirai, Keisuke

“…Summary Introduction The phosphotidylinositol-3 kinase (PI3K)/serine–threonine kinase (AKT)/mammalian target of rapamycin (mTOR) signaling pathway is…”
Get full text

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection by Muir, Andrew J., Shiffman, Mitchell L., Zaman, Atif, Yoffe, Boris, de la Torre, Andrew, Flamm, Steven, Gordon, Stuart C., Marotta, Paul, Vierling, John M., Carlos Lopez‐Talavera, Juan, Byrnes‐Blake, Kelly, Fontana, David, Freeman, Jeremy, Gray, Todd, Hausman, Diana, Hunder, Naomi N., Lawitz, Eric

“…Interferon lambda 1 (IFN‐λ1) is a type III IFN that produces intracellular responses similar to those of IFN‐α but in fewer cell types because of differences…”
Get full text

Abstract B152: Clinical pharmacokinetics of an improved tablet formulation of ONT-380 in HER2+ metastatic breast cancer patients by Vo, Alex C., Walker, Luke, Hausman, Diana, Peterson, Scott

“…Abstract Background: ONT-380 is an orally active, reversible small molecule HER2 kinase inhibitor with nanomolar potency and 500-fold selectivity compared to…”
Get full text

Phase 1 study of ZW25, a bispecific anti-HER2 antibody, in patients with advanced HER2-expressing cancers by Hausman, Diana Felice, Hamilton, Erika Paige, Beeram, Muralidhar, Thimmarayappa, Jamuna, Ng, Gordon, Meric-Bernstam, Funda

“…Abstract only TPS215 Background: HER2 is expressed above normal levels by many cancers, including a range of gastrointestinal tumors. While HER2 can contribute…”
Get full text

A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma by Bowles, Daniel W., Kochenderfer, Mark, Cohn, Allen, Sideris, Lucas, Nguyen, Nghia, Cline-Burkhardt, Vivian, Schnadig, Ian, Choi, Minsig, Nabell, Lisle, Chaudhry, Arvind, Ruxer, Robert, Ucar, Antonio, Hausman, Diana, Walker, Luke, Spira, Alexander, Jimeno, Antonio

“…The phosphotidyinositol-3 kinase (PI3K) pathway in frequently activated on metastatic colorectal carcinoma (CRC). We combined a novel PI3K inhibitor, PX-866,…”
Get full text

A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck by Bowles, Daniel W., Senzer, Neil, Hausman, Diana, Peterson, Scott, Vo, Alex, Walker, Luke, Cohen, Roger B., Jimeno, Antonio

“…Summary Background This phase I, dose-finding study determined the safety, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), and antitumor activity…”
Get full text

A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer by Levy, Benjamin, Spira, Alexander, Becker, Daniel, Evans, Tracey, Schnadig, Ian, Camidge, D Ross, Bauman, Julie E, Hausman, Diana, Walker, Luke, Nemunaitis, John, Rudin, Charles M, Halmos, Balazs, Bowles, Daniel W

“…The phosphotidylinositol-3 kinase/serine-threonine kinase (AKT)/mammalian target of rapamycin signaling pathway is frequently altered in non-small-cell lung…”
Get more information

Phase 1 dose escalation of ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers by Meric-Bernstam, Funda, Beeram, Muralidhar, Blum, Mariela A., Hausman, Diana Felice, Infante, Jeffrey R., Patnaik, Amita, Piha-Paul, Sarina Anne, Rasco, Drew W., Rowse, Gerry, Thimmarayappa, Jamuna, Tolcher, Anthony W., Hamilton, Erika Paige

“…Abstract only 1035 Background: The HER2 receptor is expressed across a range of cancers (ca) although expression and heterogeneity vary greatly within and…”
Get full text

Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers by Meric-Bernstam, Funda, Beeram, Murali, Mayordomo, Jose Ignacio, Hanna, Diana L., Ajani, Jaffer A., Blum Murphy, Mariela A., Murthy, Rashmi Krishna, Piha-Paul, Sarina Anne, Bauer, Todd Michael, Bendell, Johanna C., El-Khoueiry, Anthony B., Lenz, Heinz-Josef, Press, Michael F., Royer, Nels, Hausman, Diana Felice, Hamilton, Erika Paige

“…Abstract only…”
Get full text